Download Savaraj - 1 UNIVERSITY OF MIAMI Curriculum Vitae 1. Date: 9/2014

UNIVERSITY OF MIAMI
Curriculum Vitae
1. Date: 9/2014
I. PERSONAL
2. Name:
Niramol Savaraj
3. Office Phone:
(305)575-3143
6.
Current Academic Rank:
Research Professor
7.
Primary Department:
Medicine
8. Citizenship:
U.S.
II.HIGHER EDUCATION
Mahidol University, Bangkok, Thailand
B.S.
1970
Mahidol University, Bangkok, Thailand
M.D.
1973
American Board of Internal Medicine
l976
American Board of Medical Oncology
l979
American Board of Hematology
l980
Washington D.C.
7950 - Renewal No. 45l2
State of Texas
F5367
III.EXPERIENCES
1985–present
Attending physician, Section of
Hematology/Oncology, Veterans Administration
Medical Center, Miami, FL.
2004-present
Research Professor, University of Miami School of
Medicine
Graduate faculty; Cancer Cell Biology. University of
Miami Miller School of Medicine
1993-2003
Adjunct Professor, University of Miami Miller School of
medicine
l985-1992
Associate Professor of Oncology, University of
Savaraj - 2
Miami School of Medicine, Sylvester Comprehensive
Cancer Center, Miami, FL.
9/1985
Associate Professor of Medicine, Department of
Chemotherapy Research, University of Texas System
Cancer Center, M.D. Anderson Hospital and Tumor
Institute, Houston, TX.
l98l-l985
Assistant Internist and Assistant Professor of
Medicine, Department of Developmental Therapeutics,
University of Texas System Cancer Center, M.D.
Anderson Hospital and Tumor Institute, Houston, TX.
l980-l98l
Faculty Associate, Department of Developmental
Therapeutics, University of Texas System Cancer
Center, M.D. Anderson Hospital and Tumor Institute,
Houston, TX.
l979
Consultant in Oncology, Veterans Administration
Medical Center, Miami, FL.
l979
Instructor, Department of Oncology and
Comprehensive Cancer Center for the State of
Florida, University of Miami School of Medicine,
Miami, FL.
IV. PUBLICATIONS
Scientific Articles in Referred Journals
1. Savaraj N, Allen LM, Sutton C, and Troner M:
Immunology
modification of adriamycin cardiotoxicity. Res Commun Chem Path and
Pharmacol 29:549-559, l980.
2. Savaraj N, and Troner MB: Aminoglutethimide in the treatment of
metastatic breast cancer. Med and Ped Oncol 8:25l-263, l98l.
3. Lian EC-Y and Savaraj N: Effect of platelet inhibitors on the
platelet aggregation induced by plasma from patients with TTP.
Blood 58:354-359, l98l.
4. Valdivieso M, Bedikian AY, Burgess M, Savaraj N, Jeffers W, and
Bodey GP:
Phase I clinical study of dihydroxyanthracenidione
administered on a 5-day intravenous schedule. Can Treat Rpt 65:84l844, l98l.
5. Savaraj N, Lu K, Valdivieso M, Burgess MA, Umsawasdi T, Benjamin RS,
and Loo TL: Clinical pharmacokinetics of l,4'-Dihydroxy-5,8 Bis (2(2-Hydroxyethyl) (amino)-ethyl)amino)9,l0-Anthracededione.
Clin
Pharm and Thera 31:32l-3l6, l982.
6. Savaraj N, Lu K, and Loo TL: Clinical pharmacology of Mitoxantrone.
Can Chemo Pharmacol 8:ll3-ll7, l982.
7. Savaraj N, Lu K, Feun LG, Leavens ME, Stewart DJ, Benjamin RS, and
Loo TL: Intracerebral penetration and tissue distribution of AZQ. J
of Neuro-Onc l:l5-l9, l983.
2
Savaraj - 3
8. Feun LG, Stewart DJ, Leavens ME, Burgess MA, Savaraj N, Benjamin RS,
and Bodey GP: A phase II trial of PCNU in primary malignant brain
tumors. J of Neuro-Onc l:45-48, l983.
9. Lu K, Savaraj N, Huang MT, Moore D, and Loo TL: High performance
liquid chromatography (HPLC) of the new antineoplastic CL 2l6-942
Bisantrene. J of Liquid Chrom 5(7):l323-l328, l982.
10. Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung
WKA, and Benjamin RS: A pilot study of CDPP and radiation therapy
in high grade astrocytoma. J of Neuro-Onc l:l09-ll3, l983.
11. Feun LG, Savaraj N, Lu K, Guo ZG, Raulston G, Benjamin RS, and Loo
TL:
The Benzoquinone (AZQ, NSC- l82986) by intracarotid or
intravenous administration in beagles.
J of Neuro-Onc l:2l9-224,
l983.
12. Loo TL, Liu J, Lu K, and Savaraj N: Clinical pharmacokinetics of 5Methyltetrahydrohomofolate. Cancer Res 43:92l-924, l982.
13. Lu K, Savaraj N, Yap BVS, Bedikian AY, Feun LG, and Loo TL:
Clinical Pharmacology of 2-5'-Diazinidinyl-3-6-Biscarboethoxy-aminol,4-Benzoquinone (AZQ). Eur J Can and Clin Oncol l9:603-606, l983.
14. Guo ZG, Savaraj N, Feun LG, Lu K, Stewart DJ, Luna M, Benjamin RS,
and Loo TL: Tumor penetration of AMSA in man. Can Invest l:475478, l983.
15. Feun LG, Wallace S, Stewart DI, Chuang VP, Leaven ME, Burgess MA,
Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, and
Field WS: Intracarotid infusion of cis-diamminedichloroplatinum in
the treatment of recurrent, malignant brain tumors. Cancer 54:794799, l984.
16. Wright KC, Charnsangavej C, Wallace S, Chuang VP, Savaraj N.:
Regional isolation-perfusion: an experimental percutaneous approach
tested and compared with arterial occlusion-infusion. Cardiovasc
Intervent Radiol. 1984;7(6):294-8.
17. Feun LG, Yung WKA, Leavens ME, Burgess MA, Obbens EAMT,
Savaraj N, Stewart DJ, Benjamin RS, Field WS, and Bodey
II trial of 2,5-Diaziridinyl 3,6-BIS (Carboetnoxy l,4
(AZQ, NSC l82986) in recurrent primary brain tumor.
2:13-l7, l984.
Bedikian AY,
GP: A phase
Benzoquinone
J Neuro-Onc
18. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA,
Benjamin RS, McKelvy E, and Krakoff I: Phase I study of tricyclic
nucleoside phosphate using a 5-day continuous infusion schedule.
Cancer Res 44:3608-36l2, l984.
19. Feun LG, Wallace S, Yung WKA, Lee Y-Y, Leavens ME, Moser R, Savaraj
N, Burgess MA, et al:
Phase I trial of intracarotid BCNU and
cisplatin in patients with malignant intracerebral tumors. Cancer
Drug Delivery l:239-245, l984.
20. Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Luna M, Benjamin
RS, Keating MJ, and Loo TL:
Human tissue distribution of 4'-(9-
3
Savaraj - 4
acridinylamino)-methanesulfon-m-anisidide
(NSC
Cancer Chemother Pharmacol 12:ll6-ll9, l984.
l4l549,
AMSA).
21. Lu K, Savaraj N, and Loo TL:
Pharmacological disposition of l,4dihydroxy-5-8
Bis
2
(2-hydroxyethyl)amino
ethyl
amino-9,l0anthracedendione dihtdrochloride in the dog.
Cancer Chemother
Pharmacol 13:63-66, l984.
22. Obbens EAMT, Feun LG, Leavens ME, Savaraj N, Stewart DJ, and
Gutterman JN:
Phase I clinical trial of intralesional and
intraventricular leukocyte interferon for intracranial malignancies.
J of Neuro-Onc 3:6l-67, l985.
23. Feun LG, Savaraj N, and Ozarda AT:
Cisplatin in medulloblastoma
with extracranial metastasis:
A case report. Cancer Treat Rpts
68:l307-l309, l984.
24. Feldman LD, Feun LG, Benjamin RS, Plager C, Papadopoulos N, Savaraj
N, Burgess MA, and Bodey GP: A phase II trial of PCNU in patients
with malignant mesothelioma and central nervous system metastases.
Am J of Clin Onc 8:215-217, l985.
25. Feun LG, Yung WKA, Stewart DJ, Savaraj N, and Bodey GP: Phase II
trial of methyl-GAG in malignant primary brain tumors. Cancer Treat
Rpts 69:329-330, l985.
26. Lu K, Savaraj N, and Newman RA: Liquid chromatographic separation
and quantitation of benzisoquinolinedine (NSC-308847, nafidimide)
from biological fluids. J. of Chromat. 345(2):408-412, l985.
27. Savaraj N, Feun LG, Lu K, Wallace S, Fields WS, and Loo TL:
Clinical pharmacology of intracarotid etoposide. Cancer Chemo Pharm
l6:292-294, l986.
28. Savaraj N, Lu K, Feun LG, Burgess MA, and Loo TL: Comparison of CNS
penetration, tissue distribution and pharmacology of VP l6-213 by
intracarotid and intravenous administration in dogs.
Cancer
Investigation 5(1):11-6, 1987.
29. Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, and Loo
TL: Clinical pharmacology of homoharringtonine. Cancer Treat Rep
70:l403-l407, l986.
30. Lu K, Savaraj N, Yap B-S, Feun LG, Umsawasdi T, and Loo TL:
Clinical pharmacokinetics of 9, l0k-anthracenedi-carboxaldehyde-bis[(4,5, dihydro-lH-imidazole-2-yl)Hydrazone]k-dihydrochloride.
Canc
Chemo Pharm l6:l56-l59, l986.
31. Lu K, Savaraj N, Kavanagh J, Feun LG, Burgess M, Bodey GP, and Loo
TL: Clinical pharmacology of 4-demethoxydaunorubicin DMDR. Cancer
Chemother Pharmacol l7:l43-l48, l986.
32. Pasterz R, Savaraj N, and Burgess M: Analysis of prognostic factors
in patients with metastatic carcinoma of unknown primary. J of Clin
Oncology 4:l652-l657, l986.
33. Kavanagh JJ, Yeung K, Savaraj N, and Krakoff I:
4
Phase I clinical
Savaraj - 5
evaluation and intravenous 4-demethoxydaunorubicin.
Clin Oncol 2l:ll87-ll89, l985.
Eur J Cancer
34. Savaraj N, Feun L, Lu K, Leavens M, Moser R, and Loo TL: Central
nervous system (CNS) penetration of homoharringtonine. J of Neuro
Oncol 5:77-8l, l987.
35. Feun L, Lee YY, Yung W-KA, Savaraj N, and Wallace S: Intracarotid
VP-l6 in malignant brain tumors. J of Neuro Oncol 4:397-40l, l987.
36. Khorsand J, Katz RL, and Savaraj N:
Malignant carcinoid of the
pancreas: A cytologic, ultrastructural, and immunocytochemical study
of a case diagnoised by fine-needle aspiration of a supraclavicular
node metastasis. Diag Cytopath 1987 Sep;3(3):222-7.
37. Vogel CL, Gorowski, E, Davila E, Eisenberger M, Kosinski J, Agarwal
RP, and Savaraj, N: Phase I clinical trial and pharmacokinetics of
weekly ICRF - l87 (NSC l69780): Infusion in patients with solid
tumors. Invest New Drugs. 1987;5(2):187-98.
38. Wright KC, Stephens LC, Wallace S, Savaraj N, and Feun LG:
Experimental
combination
chemotherapy:
Intracarotid
versus
intravenous administration of azuridinylbenzoquinone BCNU and
cisplatin in dogs. Chemotherapy 33:438-444, 1987.
39. Lu K, Savaraj N, Feun LG, Zhengang G, Umsawasdi T, and Loo TL:
Pharmacokinetics of homoharringtonine in dogs.
Cancer Chem Pharm
21:139-142, 1988.
40. Feun LG, Savaraj N, Legha SS, Silva EG, Benjamin RS, Burgess MA:
Chemotherapy for metastatic merkel cell carcinoma. Cancer 62:683685, 1988.
41. Clayton C, Logothetis C, Savaraj N, Fritsche H, Gietner A, and
Samuels M: The correlation of vinblastine pharmacokinetics to
toxicity in testicular cancer patients.
J Clin Pharmacol 28:714718, 1988.
42. Savaraj N, Ling J, Lu K, Feun LG, and Hsu TC: Genotoxicity of 1HBenz[DE] isoquinoline-1 3(2H0-Dione, 5 Amino-2-[2-(Dimethylamino)
ethyl] (BIDA) in human lymphocytes. Cancer Investigation 7:117-121,
1989.
43. Hussein AM, Savaraj N, Feun LG, Ganjei P, and Donnelly E:
Carcinomatous meningitis from transitional cell carcinoma of the
bladder: Case report. J Neuro Onc 7:255-260, 1989.
44. Lampidis T, Castello C, Gliglio A, Pressman B, Viallet P, Trevorrow
K, Valet G, Tapiero H, and Savaraj N: Relevance of chemical change
of Rhodamine dyes to multidrug resistance.
Biochem Pharm 38:23,
4267-4271, 1989.
45. Hussein AM, Feun LG, Savaraj N, East D, Hussein D. Carcinoid tumor
presenting as central nervous system symptoms. Case report and
review of literature.
Amer Jour of Clin Onc 13(1):251-5, 1990.
46. Lampidis T, Savaraj N, Valet K, Trevorrow K, Fourcade A, and Tapiero
5
Savaraj - 6
H:
Relationship of chemical change of anticancer agents to
increased accumulation and cytotoxicity in cardiac and tumor cells:
Relevance to multidrug resistance.
J of Cellular Pharm 1:16-22,
1990.
47. Serafini AN, Kotler J, Feun LG, Dewanjee M, Savaraj N, Robinson D,
Sfakianaki, Abrams P, Goodwin D, and Nelp W: Technetium-99m labeled
monoclonal antibodies in the detection of metastatic melanoma. Clin
Nucl. Med. 14(8):580-7, 1989.
48. Sridhar KS, Samy TSA, Koch G, Agarwal RP, Duncan RC, Ganz WI,
Benedetto P. Feun LG, Savaraj M, Gross J, Krishan A, and Zubrod CG:
Phase I study of 4'0' - Tetra hydropyranyl adriamycin. Cancer 1990
Nov 15;66(10):2082-91 .
49. Feun LG, Maor M, Stewart PJ, Leavens ME, Young WK, Savaraj N,
Burgess MA, Benjamin RS. Fields WS, and Bodey GP: A pilot study of
PCNU and cranial radiation therapy in the treatment of patients with
malignant gliomas. Oncology 47:389-392, 1990.
50. Feun LG, Savaraj N, Landy H, Levin H, Lampidis T: Phase II study of
homoharringtonine in patients with recurrent primary malignant
central nervous system tumors. J Neuro Onc 9:159-163, 1990.
51. Gliglio A, Savaraj N, Cantello C, Tapiero H, White L, Kalondis D,
and Lampidis TJ: Comparative effects of memogaril and adriamycin on
cardiac and multidrug resistant tumor cells.
J Cellular Pharm
1:124-128, 1990
52. Feun LG, Albores S, and Savaraj N: Osteosarcoma arising adjacent to
a longstanding ameloblastoma.
Oral Surgery, Oral Medicine, and
Orial Pathology, 71-79, 1991.
53. Ardalan B, Stridhar K, Reddy R, Benedetto P, Richman S, Waldman S,
Morrell L, Feun L, Savaraj N, Livingstone A.: Phase I study of high
dose 5-fluorouracil and high dose Leucovorin with low dose
phosphonacetyl-L-aspartic
acid
in
patients
with
advanced
malignancies. Int J Radiat Oncol Biol Phys. 1992;22(3):511-4.
54. Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell
L, Feun L, Savaraj N, Fodor M, Livingstone A.: A phase I, II study
of high-dose 5-fluorouracil and high-dose leucovorin with low-dose
phosphonacetyl-L-aspartic
acid
in
patients
with
advanced
malignancies. Cancer. Sep 15;68(6):1242-6, 1991.
55. Sridhar KS, Hussein AM, Benedetto P, Waldman SM, Feun LG, Savaraj
N, Richman SP, Ardalan B, Desai P.: Phase II trial of mitoxantrone
in head and neck carcinoma.Am J Clin Oncol. Aug;14(4):298-304,
1991.
56. Feun LG and Savaraj N:
Detection of occult bone metastases by
magnetic resonance imaging. J Fl Med Assoc 88:881-883, 1990.
57. Feun LG, Gonzalez R, Savaraj N, Hanlon H, Collier M, Robinson WA,
and Clendennin NJ:
Phase II trial of piritrexim (301u, 74, PTX)
capsules
in
metastatic
melanoma
using
prolonged,
low-dose
administration. JCO 9:464-467, 1991.
6
Savaraj - 7
58. Feun LG, Savaraj N, Lee YY, Landy H, Martinez-Prieto J,
Charnsangavej C, Post D, Lee KF, Wallace S, Bowen B, Kochan JP, and
Yung WKA:
A pilot clinical and pharmacokinetic study of
intracarotid cisplatin and bleomycin. Selective Cancer Therapeutics
1991 Spring;7(1):29-36.
59. Lampidis TJ, Kolonias D, Savaraj N, and Rubin R: Cardiostimulatoru
and anti-arrhythmic activity of tubulin-binding agents. Proc Natl
Acad Sci U.S.A. 89:1256-1260,1992.
60. Trevorrow KW, Valet G, Tapiero H, Savaraj N, and Lampidis TJ:
Carboxylic ionophores increased rhodamine 123 retention in multidrug
resistant frienf leukemic cells with increased MDR1 gene expression.
J Cell Pharmacol 4:29-36, 1991.
61. Feun LG, Savaraj N, Benedetto P, Sridhar K, Hanlon J, Collier M.
Richman S, and Clendennin NJ: Phase I trial of piritrexim (BW 301,
PTX) capsules using prolonged low-dose administration. JNCI 83:5155, 1991.
62. Ardalan B, Sridhar K, Benedetto P, Richman S, Waldman S, Morrell L,
Feun LG, Savaraj N, and Livingstone A:
Phase I and II study of
high-dose 5-Fluorouracil and high dose of Leucovorin with lose-dose
PALA in patients with advanced malignancies.
Cancer. 1991 Sep
15;68(6):1242-6 (In press).
63. Savaraj N, Feun, Lu K, Wang C, and Loo TL: Pharmacology
intrathecal VP-16-213 in dogs. J. Neuro-Onc. 13:211-215,1992.
of
64. Moore M, Donnelly, Feun LG, and Savaraj N:
Successful Therapy of
peritoneal mesothelioma with intraperitoneal chemotherapy alone Am.
J. of Clin. Onc. 1992 Dec;15(6):528-30.
65. Brouty-Boye D, Kolonias D, Savaraj N, and Lampidis TJ: Smooth muscle
actin expression in cultureed cardiac fibroblasts of new born rat In
Vitro Cell Del. Biol. 28A:1-4, 1992.
66. Feun LG, Savaraj N, Bujnoski J, Nadeem S.: Spinal cord compression
produced by osteomyelitis mimicking spinal epidural metastasis.Am J
Clin Oncol. Apr;15(2):174-9, 1992.
67. Dellinger M, Pressman B, Higgenson C, Kolonias D, Savaraj N, and
Lampidis TJ: Structure function activity of simple lipophilic
cations in multidrug resistant cells. Cancer Research 52:6385-6389,
1992.
68. Savaraj N, Feun L, Blyden G, et al:
pharmacological study of intra-arterial
Cancer Biother. 8(1):38-42,1993.
A pilot
infusion
clinical and
of Thiotepa.
69. Feun LG, Blyden G, Yrizarry J, Dorvil M, Waldman S, Benedetto P,
Donnelly E, Curtas J, George M, and Savaraj N:
Clinical and
Pharmacological Study of Intrahepatic Artery Infusion of Thiotepa.
Cancer Biother. 8(1):43-48, 1993.
70. Cheng CC, Dong Q, Liu LF, Chen AY, Savaraj N, and Chou TC: Design
of Antineoplastic Agents on the basis of the "2-Phenylnaphthalenetype" Structure Pattern II Synthesis and biological activity studies
7
Savaraj - 8
of Benzo b naphtho 2.3-d furan-6,11- dione derivatives.
Chem. 1993.
J. of Med.
71. Hsu TC, Savaraj N, Trizna Z, Feun L, Furlong C, Schantz SP, Shirley
L, and Shen DY:
Cytogenetic studies on the genotoxicity of 4nitroquinoline-1-oxide on human cells in vitro.
Int. J. of Onc.
3:823-826, 1993.
72. Hsu TC, Feun L, Trizna Z, Savaraj N, Shirley LR, Furlong CL, Schantz
SP, Neber RS, Shen TJ, and Kucuk O: Differential sensitivity among
human subpopulations in response to 4-nitroquinline-1-oxide and to
bleomycin. Int. J. of Cancer 3:827-830, 1993.
73. Sridhar KS, Thurer RJ, Markoe AM, Chatoor HT, Fountzilas G, Raub
WJ, Savaraj N, Beattie EJ.:Multidisciplinary approach to the
treatment of locally and regionally advanced non-small cell lung
cancer: University of Miami experience. Semin Surg Oncol. MarApr;9(2):114-9, 1993.
74. Savaraj N, Wu CJ, Lampidis TJ, Chua L, and Feun L:
cytotoxicity of U-73975 in multidrug resistant and
resistant cells. J. of Cell. Pharm. 2:103-106, 1994.
In vitro
cisplatin
75. Savaraj N, Lampidis T, Zhao ZY, Wu CJ, Teeter LD, and Kuo MT:
Multidrug resistant cells selected with different drugs is
associated with overproduction of different P-glycoproteins. Cancer
Investigation 12(2):138-144, 1994.
76. Lampidis TJ, Kolonias D, Savaraj N, and Rubin RW:
The effects of
tubulin-binding agents on cardiac cell contractility in vitro. J.
Cell Pharmacol. 3:1-2, 1992.
77. Zhao JY, Savaraj N, Song r, Priebe W, and Kuo MT: Overexpression of
P-Glycoprotein but not its mRNA in Multidrug Resistant cells
selected with Hydroxyrubicin
Anticancer Res. 14:1735-1742,1994.
78. Feun LG, Reddy KR, Yrizarry JM, Savaraj N, Guerra JJ, Purser RK,
Waldman S, Levi JU, Moffat F, Morrell L, Livingstone AS, Ardalan B,
and Benedetto P.
A phase I study of chemoembolization with
cisplatin and lipiodol for primary and metastatic liver cancer. Am
J Clin Oncol 17:405-410, 1994.
79. Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P,
Livingstone AS, Ardalan B, Levi JU, Parker T, and Schiff ER.
A
phase II trial of recombinant leukocyte interferon plus doxorubicin
in patients with hepatocellular carcinoma. Am J Clin Oncol 17:393395, 1994.
80. Feun LG, Savaraj N, Benedetto P, Waldman S, Collier M, and
Clendennin NJ.
Oral piritrexim in advanced bladder cancer: An
effective drug after progression on MVAC chemotherapy?
Am J Clin
Oncol, 17 (5):448-451, 1994.
81. Feun LG, Raub WA, Jr., Duncan RC, Moffat F, Savaraj N, Nemeth A,
Markoe A, and Trapido E.
Melanoma in a Southeastern Hispanic
Population. Cancer Detection and Prevention 18 (2):145-152, 1994.
82. Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser
8
Savaraj - 9
K, and Clendennin NJ. Phase II trial of piritrexim and DTIC using
an alternating dose schedule in metastatic melanoma.
Am J Clin
Oncol 17:448-451, 1994.
83. Feun LG, Savaraj N, and Landy JH.
J Neuro-Oncol 20:165-176, 1994.
Drug resistance in brain tumors.
84. Podack ER, Zhao D, Ohe Y, Nishio M, Cassileth PA, Roderick JF,
Spielman J, and Savaraj N: Gene therapy for small cell lung
carcinoma and demonstration of tumor specific CTL restricted by HLA
A2.
Contemporaneous Publication of the Proceedings of the XVI
International Cancer Congress, pp 1-4, 1994.
85. Brouty-Boye D, Kolonias D, Wu CJ, Savaraj N, and Lampidis TJ:
Relationship of Multidrug resistance to Rhodamine-123 selectivity
between carcinoma and normal epithelial cells: Taxol and Vinblastine
modulate drug efflux. Cancer Res.55:1633-1638,1995.
86. Cassileth PA, Podack E, Sridhar K, Savaraj N, Hanlon J.Phase: I
study of transfected cancer cells expressing the interleukin-2 gene
product in limited stage small cell lung cancer.Hum Gene Ther.
Mar;6(3):369-83, 1995.
87. Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser
K and Clendennin NJ. Phase II trial of piritrexim and DTIC using an
alternating dose schedule in metastatic melanoma. Am J Clin Oncol
18(6):488-490, 1995.
88. Feun LG, Savaraj N, Solomon J, Liebmann A and Hurley J: Phase II
trial of mitoxantrone and cisplatin in advanced non-small cell lung
cancer. Am J Clin Oncol, 19(2):190-192, 1996.
89. Xu J, Tyan T, Cedrone E, Savaraj N and Wang N: Detection of 11Q13
amplification as the origin of a homogeneously staining region in
small cell lung cancer by chromosome microdissection. Genes,
Chromosomes & Cancer, 17(3):172—178, 1996.
90. Savaraj N, Wu CJ, Xu R, Feun L, Lampidis TJ and Kuo MT:
Quantitative Multidrug Resistance Associated Protein (MRP) Gene
Expression by Competitive Reverse-Transcriptase Polymerase Chain
Reaction. Cellular Pharmacology, 3:349—354, 1996.
91. Podack ER, Nishlo M, Savaraj N, Spielman J, Casselith PA, Heike Y,
Ohe Y, Saijo N: Induction and targeting of tumor—specific CTL. J
Clin Biochem & Nutrition, 21(1):85—86, 1996.
92. Feun LG, Savaraj N, Moffat F, Robinson D, Liebmann A, Hurley J,
Raub, Jr., W. and Richman S. Phase II trial of recombinant alphainterferon (Intron) with BCNU, Cisplatin, DTIC, and Tamoxifen in
advanced, malignant melanoma Melanoma Res. 1995 Aug;5(4):273-6.
93. Savaraj N, Wu CJ, Xu R, et al: Multidrug Resistant Gene Expression
in Small Cell Lung Cancer. American Journal of Clinical Oncology,
20(4):398-483, 1997.
94. Lertratanangkoon K, Savaraj N, Scimeca JM, Thomas ML: Glutathione
depletion-induced
thymidylate
insufficiency
for
DNA
repair
synthesis. Biochem & Biophy Res Comm, 234(2):470—475, 1997.
9
Savaraj - 10
95. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L,
Savaraj N, Tapiero H and Priebe W: Circumvention of P-GP MDR as a
function of anthracycline lipophilicity and charge. Biochemistry,
36(9):2679—2685, 1997.
96. Lampidis TJ, Shi YF, Calderon CL, Kolonias D, Tapiero H, Savaraj N:
Accumulation of simple organic cations correlates with differential
cytotoxicity in multidrugresistant and —sensitive human and rodent
cells. Leukemia, 11(7):1156—1159, 1997.
97. Savaraj N, Xu R, Landy H, Lai 5, Sternau L, Solomon J, Wu CJ,
Lampidis T and Feun LG: Comparison of topoisomerase I and II
expression in primary brain tumor and lung cancer. Oncology Rep.,
4:857—861, 1997.
98. Lertratanangkoon K, Wu CJ, Savaraj N and Thomas M: Alterations of
DNA methylation by glutathione depletion. Cancer Letters, 120:149—
156, 1997.
99. Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N, Masuzawa T,
Ishikawa T: Frequent co-expression of MRP/GS-X pump and —
glutamylcysteine synthetase mRNA in drug-resistant cells, untreated
tumor cells, and normal mouse tissues. Biochem Pharmacol, 55(5):605615, 1998.
100. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T:
Doxorubicin— and daunorubicin—glutathione conjugates, but not
unconjugated drugs, competitively inhibit leukotriene C4 transport
mediated by MRP/GS-X pump. Biochem Biophys Res Commun, 247(3):859863, 1998.
101. Chang HX, Chou TC, Savaraj N, Liu LF, Yu C, Cheng CC: Design of
antineoplastic agents based on the “2-phenylnaphthalene-type”
structural pattern. 4. Synthesis and biological activity of 2chloro-3-(substituted phenoxy)-1, 4-naphthoquinones and related 5,8dihydroxy-1, 4-naphthoquinones. J Med Chem, 42(3):405-408, 1999.
102. Kolonias D, Podona T, Savaraj N, Gate L, Cossum P, Lampidis TJ:
Comparison of annamycin to adriamycin in cardiac and MDR tumor cell
systems. Anticancer Res, 19(2A):1277-83, 1999.
103. Yamzaki K, Spruill G, Rhoderick J, Spielman J, Savaraj N, and
Podack ER. Small cell lung carcinoma express shared and private
tumor antigen presented by HLA-A1 or H. Cancer Res. 15:4642-50,
1999.
104. Feun LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E,
Schawatz M, Savaraj N, Livingstone AS, Levi JU, Jeffer J, Ardlan B
and Schiff ER. A phase I study of chemoembolization with cisplatin,
thiotepa, and liiodol for primary and metastatic liver cancer. Am J
Clin Oncol 22:375-80, 1999.
105. Feun LG, Savaraj N, Hurley J, Marini A, and Lai S. A clinical trial
of intravenous viorebine tartrate plus tamoxifen in the treatment of
patients with malignant melanoma. Cancer 1:585-8, 2000.
106. Hu YP, Moraes C, Savaraj N, Priebe W, and Lampidis TJ. Tumor Cells:
10
Savaraj - 11
A model for studying whether mitochondria are target for Rhodamine
123, Doxorubicin and other drugs. Biochem Pharmacol. 2000 Dec
15;60(12):1897-905.
107. Zou JY, Howard L, Feun L, Xu R, Lampidis TJ, Wu CJ, Furst AJ and
Savaraj N. Correlation of unique 220 kd protein with vitamin D
sensitivity
in
glioma
cells.
Biochem
Pharmacol.
2000
Nov
1;60(9):1361-5.
108. Liu H, Hu YP, Savaraj N, Priebe w, Lampidis TJ. Hypersensitozation
of tumor cells to glycolytic inhibitors. Bicochemistry: 40: 5542-7,
2001.
109. Shigeru T, Hitoshi U, Sinicrope FA, Sakatani T, Sugumura K, Makino
M, Ito H, Savaraj N, Kaibara N, and Kuo MT: Expression of heavy
subunit of  glutamylcysteine synthetase in human colorectal
cancer. Int. J. Cancer 97:21-27.2002
110. Lin-Lee YC, Tatebe S, savaraj N, Ishikawa T, and Kuo M.T.
Differential sensitivities of the MRP gene family and gamma
glutamylcystenine synthetase to prooxidants in human colorectal
carcinoma cell lines with different p-53 status. Biochem.
Pharmacol.1:61 555-563, 2001
111. Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P,
Almassian B, Colacino E, Fisher J, and Mc Donald S. Phase I and
pharmacokinetic
study
of
3-aminopyridine-2-carboxaldehyde
thiosemicarbazone (3-AP) using a single intravenous dose schedule.
Cancer Chemother and Pharmacol.50(3):223-9, 2002.
112. Feun L, Savaraj N, Hurley J, Marini A. Phase II trial of Paclitaxel
and Dacarbazine with filgrastim administration in advanced malignant
melanoma Cancer Invest. 20(3):357-61, 2002.
113. Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor
cell sensitivity to glycolytic inhibitors: a strategy for solid
tumor therapy(ModelC).Biochem Pharmacol. 2002 Dec 15;64(12):174551.
114. He L, Chang HX, Chou TC, Savaraj N, Cheng CC. Design of
antineoplastic agents based on the '2-phenylnaphthalene-type'
structural pattern-synthesis and biological activity studies of
11H-indolo[3.2-c] quinoline derivatives. Eur. J Med Chem. 2003
Jan;38(1):101-7.
115. Feun LG, O’Brian C, Molina E, Rodriguez M, Jeffers L, Schiff ER.
Recombinant leukocyte interferon, doxorubicin, and 5FUDR in
patients with hepatocellular carcinoma-A phase II trial. J Cancer
Res Clin Oncol. 2003 Jan;129(1):17-20.
116. Savaraj N, Wu CJ, Wangpaichitr M, Kuo MT, Lampidis T, Robles C,
Furst AJ, Feun L. Overexpression of mutated MRP4 in cisplatin
resistant small cell lung cancer cell line: Collateral sensitivity
to azidothymidine. Int. J. of Oncol. 23(1):173-9, 2003.
117. Robles C, Furst AJ, Sriratana P, Lai S, Chua L, Donnelly E,
Solomon J, Sundaram M, Feun L, Savaraj N. Phase II study of
11
Savaraj - 12
vinorelbine with low dose prednisone in the treatment of hormone
refractory metastatic prostate cancer. Oncol. Rep.10(4):885-9, 2003
118. Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ.: Multidrug
resistance correlates with overexpression of Muc4 but inversely
with P-glycoprotein and multidrug resistance related protein in
transfected
human
melanoma
cells.
Biochem
Pharmacol.
May
1;65(9):1419-25, 2003.
119. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T.
Phase I and Pharmacokinetic study
of triapine, a potent
ribonucleotide reductase inhibitor, administered daily for five
days in patients with advanced solid tumors Clin Cancer Res.
15:9(11) 4092-100, 2003.
120. Wangpaichitr M, Landy H, Wu CJ, Feun LG, Xu R, and Savaraj N.
Procollagen-like protein as a molecular target in the treatment of
primary tumor. Scientific World Journal Jan 2:2 125-6 2002.
121. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K,
Tidmarsh GF De Young LR, and Lampidis TJ. 2-deoxy-D-glucose
increases the efficacy of adriamycin and paclitaxel in human
osteosarcoma and non-small cell lung cancer in vivo. Cancer Res.
164(1) 31-4 2004.
122. Landy H, Markoe A, Potter P, Lasalle G, Marini A, Savaraj N, Keis
I, Hero D, Wangpaichitr M, and Feun L. Pilot study of estramustine
added to radiosurgery and radiotherapy for treatment of high grade
glioma J. Neurooncol. 67:215-20. 2004.
123. Song IS, Savaraj N, Siddik Z, Liu P, Wei YG, Wu CJ, and Kuo MT.
Role of copper transporter Ctr1 in the transport of platinum-based
antitumor agents in cisplatin-sensitive and resistant cells. Mol.
Cancer. Ther.3:1543-9. 2005.
124. Maher JC. Savaraj N, Priebe W, Liu H, Lampidis TJ. Differential
sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines
correlate with GLUT-1 expression Pancreas 30:e34-9 2005.
125. Feun L, Marini A, Moffat F, Savaraj N, Hurley J and Mazumder A.
Cyclosporin
A,
alpha-interferon
and
interleukin-2
following
chemotherapy with BCNU, DTIC, cisplatin and tamoxifen: a phase II
study in advanced melanoma. Cancer Invest. 23:3-8, 2005.
126. Savaraj N, Wu, CJ, Landy H, Wangpaichitr M, Wei YJ, KuO MT, Robles
C, Furst AJ, Lampidis TJ, and Feun L. Procollagen alpha 1 type I. A
potential Aide in Histopathological Grading of Glioma.
Cancer
invest. 23(7),577-81,2005
127. Savaraj N, Wei YG, Liu P, Wu CJ, Wangpaichitr M, Xia D, Xu HJ, Hu
SX and Kuo MT. Redox Regulation of Matrix Metalloproteinase Gene
Family in Small Cell Lung Cancer Cell Free Radical Res. 39(4): 373381, 2005
128. Wu CJ, Wangpaichitr M, Feun LG, Kuo MT, Robles C, Lampidis TJ, and
Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor. Mol
Cancer. 2005 Jul 20;4(1):25-35
12
Savaraj - 13
129.Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano
A, Beneduce G, De Rosa V, Izzo F, Mclucci MT, Ensor CM, Prestayko
AW, Holtsberg Fw, Bomalaski Js, Savaraj N, Feun LG and Logan TF.
Pegylated arginine deiminase treatment of patients with metastaic
melanoma:
results
from
phase
I
and
II
studies
J.Clin.
Oncol.20:23(30: 7660-8. 2005.
130.Kuo MT, Wei YG, Yang X, Tatebe S, Liu J, Troncoso P, Sahin A, Ro
JY, Hamilton SR, and Savaraj N. Association of Fragile SiteAssociated(FSA) gene Expression with Epithelial Differentiation and
Tumor Development. Biochem.Biophy.Res.Com. 340:887-93 , 2005.
131.Wei JG, Lin-Lee YC, Yang X, Dai W, Zhao S, Rassool FV, Elgart GW,
Feun L, Savaraj N, and Kuo MT. Molecular Cloning, of chinese hamster
1q31 Chromosomal Fragile Site DNA that is important to mdr1 Gene
Amplification Reveals a Novel Gene whose expression is associated
with Spermatocytes and Adipocytes differentiation. GENE372:44-52.
2006.
132.Tien Kuo M, Savaraj N. Roles of reactive oxygen species in
hepatocarcinogenesis and drug resistance gene expression in liver
cancers. Mol Carcinog 2006, May 1;45(9) 701-9.
133.Feun L. Savaraj N.
anticancer enztme agent.
Pegylated arginine deiminase: A novel
Expert. Opin. Investig. Drug. 159&) 812-22
134.Feun LG. Marini A. Landy H Markoe A Heros D Robles C. Herrera C
and Savaraj N. Clinical trila of CPT-11 and VM26/VP-16 for patient
with recurrent brain tumor J. Neurooncol. 82(2) 177-81 2006.
135. Maher JC, Wangpaichitr M. Savaraj N. Kurtoglu and Lampidis TJ.
Hypoxia inducuble factor 1 confers resistance to the glycolytic
inhibitor 2 deoxy-D Glucose Mol. Cancer Ther. 6(2) 732-41 2007.
136.Kuo MT. Chen HH. Song IS Savaraj N. and Ishikava. The role of
copper transporter in cisplatin Resistance
Cancer Metastasis Rev.
26(1) 71-83. 2007.
137.Savaraj N, Wu CJ, Kuo MT, You M, Wangpaichitr M, Robles C, Spector
M.
and
Feun
L.
The
relationship
of Arginine Deprivation,
Argininosuccinate Synthetase and Cell Death in Melanoma. Drug Target
Insight 2:119-128 2007.
138.Vy Dinh, Feun L, Elgart G. and Savaraj, N. Merkel Cell Carcinoma.
Hematology Clinics of North America. 2: 527-544. 2007.
139.Kurtoglu M, Gao N, Shang J, Maher JJC, Lehman MA, Wangpaichitr M,
Savaraj N, Lane AN. Under normoxia, 2-deoxy-D-glucose elicit cell
death in select tumor types not by inhibition of glycolysis but by
interfering with N-linked glycosylation Mol. Cancer Ther. 6911) 349-58. 2007.
140.Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, and
Savaraj N. Arginine Deprivation as a Targeted Therapy for Cancer.
Curr. Pharma. Design 14(11):1049-57, 2008.
141.Feun L, Savaraj N. Topoisomerase I inhibitors for the treatment of
13
Savaraj - 14
brain tumor Exp. Rev. Anticancer Ther. 8(3) 707-16, 2008.
142 Wangpaichitr M. Savaraj N, Maher J, Kurtoglu and Lampidis TJ.
Intrinsically lower AKT, mTOR and HIF activity correlates with
increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung
cancer cell lines. Mol. Cancer. Ther. 7(6):1506-13, 2008
143 Wangpaichitr M, Wu CJ, You M, Kuo MT, Feun L, Lampidis TJ, and
Savaraj. Inhibition of mTOR restores cisplatin sensitivity through
down regulation of growth and antiapoptotic protein. Eur.J.Pharmacol
59(1-3)124-7
144. Chen HH, Song IS, Hossain A, Choi MK, Tamane Y, Liang ZD, Lu J,
Wu LY, Siddik Z, Klomp LW, Savaraj N and Kuo MT.
Elevated
Glutathione Levels Confers Cellular Sensitization to Cisplatin
Toxicity by Upregulation of Copper Transport hCtr. Mol. Pharmacol.
74(3):697-704, 2008
145. Liang ZD, Stockton D, savaraj N, Kuo MT. Mechanistic
Comparison
of
Human
Copper
Transporter
hCtr1-Mediated
transports between Copper Ion and Cisplatin.
Mol Pharmacol.
2009 Oct;76(4):843-53. Epub 2009
146. Tsai W-B, Aiba I, Lee S-Y, Feun L, Savaraj N, Kuo MT. Resistance
to arginine deiminase treatment in melanoma cells is associated with
induced argininosuccinate synthetase expression involving c-Myc/HIF1α/Sp4. Mol. Cancer. Ther., 2009: 3223-33.
147. Wangpaichitr M, Wu C, You M, Maher JC, Feun LG, Savaraj. N.
N′1,N′3-Dimethyl-N′1,N′3-bis(phenylcarbonothioyl) Propanedihydrazide
(Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells
through Reactive Oxygen Species (ROS). Cancers, (1), 2009:23-28
148.You M, Savaraj N, Wangpaichitr M, Wu C, Kuo M.T, Varona-Santos J,
Nguyen D, Feun L. The combination of ADI-PEG20 and TRAIL effectively
increases cell death in melanoma cell lines. Biochem Biophys Res
Commun, 394(3)2010:760-6
149. Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N,
Lampidis TJ. 2-Deoxy-D-glucose activates autophagy via ER stress
rather than ATP depletion. Cancer Chemother Pharmacol, (Epub ahead
of print), Jul-1; 2010
150. Savaraj N, You Min, Wu C.J., Wangpaichitr M, Kuo M.T., Feun L.G.
Arginine deprivation, Autophagy, Apoptosis (AAA) for the treatment
of Melanoma. Curr Mol Med, 10(4):405-412; 2010
151. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for
cancer chemotherapy with recombinant arginine-degrading enzymes.
Onco. Target, 2010
152. Wangpaichitr M, Theodoropoulos G, Wu C, You M, Feun LG, Kuo M.T.,
Savaraj N. The relationship of thioredoxin-1 and cisplatin
resistance: its impact on ROS and oxidative metabolism in lung
cancer cells. Mol Cancer Ther, 11:604-615; 2012
153. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers S.E., Wu
14
Savaraj - 15
C.J., You M, Wangpaichitr M, Kuo M.T., Sisson W, Jungbluth A.A.,
Bomalaski
J,
Savaraj
N.
Negativeargininosuccinate
synthetase
expression in melanoma tumours may predict clinical benefit from
arginine-depleting therapy with pegylated arginine deiminase. Br J
Cancer; 2012
154. Liang ZD, Tsai WB, Lee MY, Savaraj N, Kuo MT. Specificity protein
1 (sp1) oscillation is involved in copper homeostasis maintenance by
regulating human high-affinity copper transporter 1 expression. Mol
Pharmacol, 1:455-64; 2012
155. Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, Kuo M.T.
Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to
Upregulate
Argininosuccinate
Synthetase,
Leading
to
Arginine
Deiminase Resistance in Melanoma Cells. Cancer Res (Epub ahead of
printing); 2012
156. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M,
Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT.
Mechanistic basis for overcoming platinum resistance using copper
chelating agents. Mol Cancer Ther, Nov(11):2483-94; 2012
157. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity
copper transporter in copper homeostasis regulation and cisplatin
sensitivity in cancer chemotherapy. Cancer Res, Sep 15;72(18):461621; 2012
158. You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C,
Nguyen DM, Feun L. TRAIL induces autophagic protein cleavage through
caspase
activation
in
melanoma
cell
lines
under
arginine
deprivation. Mol Cell Biochem, Nov 11(1-2), 181-90; 2013.
159. Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG,
Kuo MT. Arginine Deiminase Resistance in Melanoma Cells Is
Associated with Metabolic Reprogramming, Glucose Dependence and
Glutamine Addiction, Mol Cancer Ther. 2013 Aug 29.
160. You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen
DM. Targeting of the Hedgehog signal transduction pathway suppresses
survival of malignant pleural mesothelioma cells in vitro. J Thorac
Cardiovasc Surg, Jan;147(1):508-16; 2014.
161. Liang ZD, Long Y, Chen HH, Savaraj N, Kuo MT. Regulation of the
high-affinity copper transporter (hCtr1) expression by cisplatin and
heavy metals. J Biol Inorg Chem; 2014
162.Matsangou M, Santos ES, RaezL, Gomwz JE, Dinh V, and Savaraj N.
Early stage non-small cell lung cancer , role of adjuvant
chemotherapy and promising modalities to improve prognosis and
survival outcome Future Medicine 3(1) 1-15 2014.
163. Savaraj
W, Kuo MT,
Melanomas
Cisplatin,
N, Wu CJ, Li YY, Wangpaichitr M, You M, Bomalaski JS, He
Feun LG. Targeting Argininosuccinate Synthetase Negative
Using Combination of Arginine Degrading Enzyme and
Mol Cancer Ther. 2014 (Accepted with Minor Revision)
164. Wangpaichitr M, Wu CJ, Bigford G, Theodoropoulos G, You M, Li YY,
Verona-Santos j, Feun LG, Nguyen DM, Savaraj N.Combination of
15
Savaraj - 16
arginine deprivation with TRAIL treatment as a targeted therapy for
mesothelioma. Anticancer Research. 2014 (In press)
Books and Book Chapters:
Loo TL, Savaraj N, Lu K, Yap BS, Yap HY, and Benjamin RS:
Clinical
pharmacokinetics of Vindesine. Periti P, Grasser GG (Eds).
Current
Chemotherapy and Immunotherapy, pp ll407-l409.
Proc of the l2th
International Congress of Chemotherapy, Florence, Italy, July, l98l.
Lu K, Savaraj N, and Loo TL: Pharmacokinetic studies of l,4-Dihydroxy5,8-Bis (2-(2-Hydroxyethyl)amino)ethyl)Amino-9,l0-Anthracenedion (DHAD,
NSC-279836).
Rozencweig M, Von Hoff DD, Shaquet M (eds).
New
Anticancer Drugs: Mitoxantone and Bisantrene, Raven Press, NY, l982.
Feun LG, Lee Y-Y, Wallace S, Charnsangavej C, Savaraj N, Carrasco CH,
Gianturco C, and Yung WKA:
New drugs and delivery techniques.
In:
Progress in Experimental Tumor Research. Vopl. 29:l3l-l39 (Karger,
Bosel), l985.
Lampidis TJ, Savaraj N, Valet G, Fourcade A, and Tapeiro H:
Relationship of chemical change of anticancer agents to drug
accumulation and cytotoxicity in cadaver and tumor cells: Relevance to
multidrug resistance.
John Libbey Publisher, London Vol 169:655-660,
1990.
Feun L, Kuo MT, Wu C, Wangpaichitr M, and Savaraj N.
Arginine
Deiminase and Cancer Therapy. In: Emerging Cancer Therapy: Microbial
Approaches and Biotechnological Tools. John Wiley Publishers, Chapter
9; 2010
Savaraj N, You M, Wu CJ, Kuo MT, Dinh V, Wangpaichitr M, and Feun, LG.
Targeting Argininosuccinate Synthetase in Cancer Therapy. In: Cell
Signaling & Molecular Target in Cancer, Springer Science Publishers,
Chapter 3; 2011
Savaraj N, You M, Chunjing W, Kuo MT, Dinh V, Wangpaichitr M and Feun L.
Targeting argininosuccinate synthetase in Cancer Therapy
In: Cell
Signalling and Molecular Targets in Cancer. Springer 2012 pp37-52
Feun L, Wangpaichitr M, Wu CJ, Li JJ, You M, Kuo MT, Tsai W-B, Long Y,
Savaraj N. Arginine in Cancer Therapy.
In: Arginine in Clinical
Nutrition . John Wiley and Sons, Inc , 2014 (in press).
V. PROFESSIONAL
16
Savaraj - 17
a.
GRANTS RECEIVED WITHIN THE PAST FIVE YEARS
V.A. Healthcare System

Mentor: Dept. of Veterans Affairs; Career Development Award2:
Metabolic Reprogramming: A New Paradigm for Targeting Cisplatin
Resistant Cells. (P.I.) Dr. Medhi Wangpaichitr 2012-2017.
$800,000
Woman Cancer Association

PI: Selectively Kill KRAS Mutation Non Small Cell Lung Cancer by
Exploiting ROS and Metabolic Differences 2014-2015. $50,000
State of Florida (James and Esther King)

Mentor: Florida Department of Health, Postdoc Award: Targeting RO
S and Tumor Metabolism to
Selectively Kill Cisplatin Resistant
Lung Cancer. (P.I.) Dr.Medhi Wangpaichitr 2010-2013. $165,000
NIH



Partnering-PI (RO1): Mechanism of Resistance to Arginine Deiminase
Therapy in Advance Melanoma. (Partner-PI) Dr. M.T. Kuo 2010-2015,
$200,000
Co-PI (RO1) Improving the Efficacy of Cisplatin-Based Cancer
Chemotherapy (P.I) Dr. M.T. Kuo 2010-2015
Site-PI (Multi-center Award): Validation of Multi-Gene Test for
Lung Cancer Rish: (LCRT) Protocol, Sponsor by University of
Toledo; 2011-2014
Department of Defense

PI, Profiling metabolic rewiring in serum as markers to detect
drug resistance in lung cancer, 2014. ($200,000 Pending)

Polaris group:
Targeting BRAF
arginine deprivation
$35,000
resistant
melanoma
cells
by
P.I. VA Merit Review: Overcoming Cisplatin Resistance
Inhibiting mTOR Oct.
2005-2009 total amount 483,200.
by
COMPLETED RESEARCH SUPPORT:
V.A. Healthcare System

17
Savaraj - 18

Recipient of VA merit review award since 1990.
NIH
 Co PI: NIH (R01) Arginine Deprivation: A targeted therapy for
malignant melanoma total amount $450,000 from 2004-2008. (P.I.)
Dr. Lynn G Feun.
 Co-Investigator: NIH (R01) Redox regulation of multidrug resistant
gene expression (P.I.) Dr. Marcus Tien Kuo Department of Molecular
Pathology, M.D. Anderson Cancer Center. 2006-2012. $ 650,000 total
 Collaborator: NIH (R01) Antitumor Activity of Sugar Analogs via
Blocking Glycolysis VS Glycosylation. (P.I.) Dr. T. Lampidis.
2007-2011.
Pharmaceutical Company

Determining argininosuccinate synthetase (ASS) expression in
melanoma patients treated with arginine depleting therapy. Polaris
Pharmaceutical Total amount $50,000.

A Randomized Open Label Multi-Center Study of XRP6258 at 25 mg/m2
in Combination with Prednisone Every 3 weeks Compared to
Mitoxantrone in Combination with prednisone for the treatment of
Hormone Refrcatory Metastatic Prostate Cancer Previously Treated
with a Taxotere Containing Regimen
Total amount $60,000.

Phase I-II trial of SOM230 (Pansireotide) in hepatoma Novartis
(Clinical with laboratory correlation). Total amount $200,000

Phase I-II trial of SOM230(Pansireotide) in Small Cell Lung Cancer
Novartis (Clinical with laboratory correlation). Total amount
$200,000

Phase
I-II
trial
of
combination
of
Pansireotide(SOM230)for recurrent/second line
cell
lung
cancer.
(NovartiS)
(clinical
correlation)

American Cancer Society Correlation of Unique 220 Kda protein with
vitaminD sensitivity In primary brain tumor $25,000 (mentor for
Dr. C.J. Wu).
Irinotecan
and
therapy in small
with
laboratory
2002 – 2004
Circumvention of Drug Resistance in Small Cell
Lung Cancer Using Flavopiridol. $35,000 Adventis.
2002 – 2004
Phase II study of combination of Docetaxel and
celecoxib in hormonal refractory prostate cancer.
18
Savaraj - 19
(Mentor for Dr.Carlos Robles) $80,000 (Pharmacia
and Aventis)
2001 - 2003
Phase II Study of Celecoxib, Irinotecan, 5FU and
LCV in Patients with Advanced Colorectal cancer
2000 – 2001
Procrit VS No Procrit in Outcomes of hormonal
Refractory Prostate cancer OrthoBiotec. $10,000
2000 - 2001
Phase II study of Cetuximab (Monoclonal antibody
C-225) in combination with irinotecan in relapsed
colon cancer.
1997 – 2000
NIH, $106,000 per year
Probing MRP and MDR Resistance”, Co-Investigator
10% Effort. P.I.: T.J. Lampidis, M.D.
1997 – 2000
Bayer, A Randomized, Multicenter, Double-Blind,
Placebo-Controlled Study Comparing Single-Agent
BAY 12-9566 to Matched Placebo in patients with
Small
Cell
Lung
Cancer
(SCLC)
in
Complete
Remission, $30,000
1997 – 2000
Bayer,
A
Randomized,
Double-Blind,
PlaceboControlled, Multi-Center Evaluation of BAY-12-9566
in Patients with Stage IIIA or IIIB Non Small Cell
Lung Cancer, $30,000
1997 – 2000
SmithKline Beecham, Phase II Trial of Sequential
Treatment of Topotecan and Etoposide in High and
Intermediate Grade Lymphoma, $30,000
1997 – 2000
GlaxoWellcome, Phase II study of Navelbine with
low dose prednisone in the treatment of hormonal
refractory metastatic prostate cancer, $20,000
1997 - 2000
Maxim Pharmaceuticals, Multi-Center, Randomized
Open-Label Study to Evaluate the Safety and
Efficacy
of
Combined
Immunotherapy
with
Subcutaneous
Interleukin-2,
and
Histamine
Dihydrochloride Versus Subcutaneous Interkeukin-2
Alone
in
Patients
with
Advanced
Malignant
Melanoma, $30,000
1997 – 2000
Bristol-Myers
Squibb,
A
Phase
II
Trial
of
Paclitaxel (Taxol) Administered as a Weekly One
Hour Infusion in Previously Treated Patients with
Advanced Head and Neck Cancer, $30,000
1998 - 1999
Vion Pharmaceuticals, Phase I and Pharmacokinetic
Study of 3AP.
b. Professional and Honorary Organization
 Past member of study section in Cancer Biology and Immunology NCI
19
Savaraj - 20
and NIH (1991-1995).
 Ad Hoc Member of RAG review for V.A.M.C.
 Ad hoc Member of ET-1 study section NCI, NIH. 2002-2003
 Past member of Molecular Pharmacology and Drug Design Study Section
NIH from 2003-2007
 Ad Hoc Members of Special
Therapeutics NCI, NIH.
Study
Section
Cancer
Biomarker
and
 Ad-Hoc Member of the spore grant review
 Member of SBIR drug design
 Reviews for Biochemistry and American Journal of Clinical Oncology.
 Blaffer Award Lecture
Anderson Cancer
“Targeting Therapy
Center April 2006
for
Melanoma”
M.D.
 Special Contribution Award from Department of Veteran Affair For the
excellent and commitment for the care of veteran.
 Special Contribution Award from Department of Veteran Affair. JCAHO
survey has mentioned on the survey for the excellent care we
provide in Oncology service
 Special Contribution Award from Department of Veteran affair for
Research service. (Human subject and protocol review.
 Recipient of Special Contribution Award for her leadership and
commitment to the care of veterans from V.A. Health Care System.
 Recipient of Special Contribution Award for her significant
contribution in Oncology section at V.A. which reflected in JCAHO
report.
 Recipient of Special Contribution Award for her contribution in the
field of research and development at V.A.
 Member of NIH SBIR drug discovery study section 2009-presence
 Member of NIH Broad Challenge grant 2009
 Member of NIH reviewer for Loan Repayment Program 2010-presence
 Member of Therapeutic Drug Discovery Review (NCATS)
c. POST DOCTORAL TRAINING
20
2012
Savaraj - 21
7/73
7/74
7/76
7/78
1/79
-
6/74
6/76
6/78
l2/78
l2/79
Internship, St. Vincent's Medical Center, Bridgeport, CT
Residency, St. Vincent's Medical Center, Bridgeport, CT
Oncology Fellow, University of Miami
Hematology Fellow, Medical College of Georgia
Hematology Fellow, University of Miami
d. OTHER PROFESSIONAL ACTIVITIES
Member of the American Association for Cancer Research
Member of the American Society of Clinical Oncology
e. SCIENTIFIC PRESENTATIONS
American Association of Cancer Research every year since 1979.
Multiple presentation in American Society of Clinical Oncology.
f.
PATENT
Co-patent on a series of topoisomerase I & II inhibitor compounds
with Dr. C.C. Cheng from University of Kansas.
VI.TEACHING
1. Teaching Rounds with Fellows. House staff
2. Co-adviser for graduate student: Department of Molecular Cell
Biology
Graduate
student’s
name
Dr.
John
Maher
and
Dr.
Medhi
Wangpaichitr.
Current graduate student: Mr. Hai bin, Ms. Katherine Philips. Ms.
Elizabeth Sullivan
3. Graduate student class: Cancer Biology and metabolism.
4. Fellow class: Signal transduction and cell death.
5. Post-doctoral fellow Dr. Jiang Ying Zou 1999-2000.
6. Post-doctoral fellow Dr. 2000-2001 Dr. Y.H. Zhang
7. Post doctoral fellow Dr. You Min 2007-present
8. Post-doctoral fellow Dr. Medhi Wangpaichitr 2008-2011
VII. SERVICE
DEPARTMENTAL ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES
Member of the grant reviewer: American Cancer Society institutional
grant 2002-present
Member of the grant reviewer: Sylvester Comprehensive Cancer Center,
2001-2002
EXTRA-DEPARTMENTAL ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES
1990 - 1991
Chairman, Human Studies
Center, Miami, FL.
21
Committee,
VA
Medical
Savaraj - 22
1989 - 1991
Research & Development
Center, Miami, FL.
1989 - 1990
Animal Subcommittee, VA Medical Center, Miami, FL.
1988 - 1991
Human Studies Subcommittee, Research & Development
Committee,
VA Medical Center, Miami, FL.
1987 - 1989
Equipment Subcommittee, Research & Development
Committee, VA
Medical Center, Miami, FL.
1986 - 1995
Radioisotope Committee, University of Miami, Miami,
FL.
1993 - 1994
Chairman, Space
Miami, FL.
Committee,
1996- 1997
Chairman,
Center.
Subjects
1998 – 1999
Member, Budget
Miami, FL.
1998 – 1999
Member, Space Committee, VA Medical Center, Miami,
FL.
1999 – 2003
Member, Equipment Subcommitte, VA Medical Center,
Miami, FL.
1999 – 2003
Member, Biohazard Safety Subcommittee, VA Medical
Center, Miami, FL.
2000 – 2001
member Human Subjects Committee, VA Medical Center,
Miami, FL.
2002- 2006
Alt. member of Human Subject committee. VAMC.
200720072008-
Human
Committee,
V.A.
Medical
Committee,
Subcommittee,
VA
VA
Supervise summer students from minority program.
22
Center,
VA
Medical
Medical
Center,
Member of Human Subject committee. VAMC
Ad-hoc Member of R&D committee VAMC
Member of the Promotion and tenure committee
COMMUNITY SERVICES
Medical